Dr. Conley is a biotech executive with a track record of advancing disruptive platforms in drug development. Dr. Conley is Chief Executive Officer at Renasant Bio, a biopharmaceutical company dedicated to transforming the treatment of ADPKD. Previously, Dr. Conley was CEO at Federation Bio, a clinical stage biotech where she advanced microbial cell therapies in renal disease, autoimmunity and cancer. Prior to that she spent over a decade at 23andMe, where she helped scale the company from 30 employees into the world’s leading platform for genetic-driven drug discovery. As the head of business development at 23andMe, she architected visionary partnerships across pharma and biotech.
In addition to serving on the board of Renasant Bio, Dr. Conley serves on the boards of Nuvalent and TMRW Life Sciences and formerly served on the boards of Medrio, Lesbians Who Tech and the UCSF Alliance Health Project.
Dr. Conley has received numerous awards and honors, including SF Business Times Most Influential Women in Business, Endpoints 20 Biopharma Leaders Under 40, Business Insider’s 30 Biotech Leaders Under 40, and Google Ventures 25 Women shaping the future of Technology.
Prior to industry, Dr. Conley was a research fellow at the National Institutes of Health and is co-author on more than 35 academic publications. She earned her Ph.D. in Neuroscience from Stanford University and graduated summa cum laude from Vanderbilt University with a B.A.
What is Emily Conley's net worth?
The estimated net worth of Emily Conley is at least $228,563.19 as of August 23rd, 2024. Dr. Conley owns 2,507 shares of Nuvalent stock worth more than $228,563 as of November 21st. This net worth evaluation does not reflect any other investments that Dr. Conley may own. Learn More about Emily Conley's net worth.
How do I contact Emily Conley?
Has Emily Conley been buying or selling shares of Nuvalent?
Emily Conley has not been actively trading shares of Nuvalent during the past quarter. Most recently, Emily Conley sold 3,334 shares of the business's stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $85.02, for a transaction totalling $283,456.68. Following the completion of the sale, the director now directly owns 2,507 shares of the company's stock, valued at $213,145.14. Learn More on Emily Conley's trading history.
Who are Nuvalent's active insiders?
Are insiders buying or selling shares of Nuvalent?
During the last year, insiders at the sold shares 45 times. They sold a total of 3,575,429 shares worth more than $312,854,115.90. The most recent insider tranaction occured on October, 31st when CFO Alexandra Balcom sold 10,000 shares worth more than $891,900.00. Insiders at Nuvalent own 12.5% of the company.
Learn More about insider trades at Nuvalent. Information on this page was last updated on 10/31/2024.
